Application of secretory globin 1A1 in preparation of medicine for relaxing airway smooth muscle

By secreting globin 1A1, the calcium response in the airway smooth muscle cells was suppressed, and the side effects and drug resistance problems of existing drugs were solved in the treatment of airway hyperresponsive diseases, and effective airway smooth muscle relaxation was achieved, providing a new Methods for treating respiratory diseases such as COPD.

CN118903380APending Publication Date: 2024-11-08SUN YAT SEN UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411031950.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-30
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

When existing drugs are used to treat airway hyperreactive diseases such as asthma and COPD, they are prone to side effects and easily lead to clinical drug resistance. There is no effective drug for diastolic airway smooth muscle.

Method used

Secret globulin 1A1 is used to inhibit the calcium response in smooth muscle cells and reduce the contraction of airway smooth muscle, thereby achieving the effect of diastolic airway smooth muscle, and is prepared as a clinically acceptable dosage form such as aerosols and sprays.

Benefits of technology

Effectively reducing the contraction response of airway smooth muscle, reducing the tone of airway smooth muscle, and significantly inhibiting the contraction of airway smooth muscle induced by choline substances, is of great clinical significance, especially in the treatment of respiratory diseases such as COPD.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903380A_ABST
    Figure CN118903380A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicines, and particularly relates to application of secretory globin 1A1 in preparation of a medicine for relaxing airway smooth muscles. Experimental exploration finds that the secretory globin 1A1 can effectively reduce calcium reaction in airway smooth muscle cells for the first time, so that the contraction degree of the airway smooth muscle is obviously inhibited, a good treatment effect of relaxing the airway smooth muscle is achieved, and the application of the secretory globin 1A1 in preparation of the medicine for relaxing the airway smooth muscle is developed. Besides, the secretory globin 1A1 can effectively relieve airway smooth muscle tension of a COPD model mouse, so that the secretory globin 1A1 can be used for treating respiratory system diseases such as COPD caused by airway smooth muscle contraction or bronchus spasm, and has important clinical significance.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to the application of secretoglobin 1A1 in the preparation of a medicine for relaxing airway smooth muscle. Background Art

[0002] Airway smooth muscle (ASM) is mainly located on the dorsal side of the airway cartilage ring. As an important tissue constituting the bronchi, its physiological activities directly or indirectly affect the normal physiological activities of the airways. The contraction degree of ASM is closely related to respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Excessive contraction of ASM is the main cause of airway hyperresponsiveness. At present, high-dose treatment with drugs for bronchial dilation such as β-adrenergic receptor agonists and cholinergic receptor antagonists may cause side effects such as increased heart rate and muscle tremors, and long-term single use is prone to clinical drug resistance. Therefore, it is necessary to develop new drugs with high safety for targeted treatment of airway hyperresponsiveness diseases.

[0003] Secretoglobin family 1A member 1 (SCGB1A1), also known as CCSP (club cell secretory protein), is a member of the secretoglobin family and is mainly secreted by the club cell subtype in the airway epithelium. Current studies have shown that secretoglobin 1A1 plays a negative regulatory role in acute and chronic lung inflammation, inhibiting the aggregation of neutrophils. However, the regulatory effect of secretoglobin 1A1 on airway smooth muscle is still unclear, and there are no reports at home or abroad on the use of secretoglobin 1A1 to relax airway smooth muscle to treat respiratory diseases caused by bronchospasm. Summary of the invention

[0004] The purpose of the present invention is to overcome the shortcomings and deficiencies of the prior art and provide the use of secretoglobin 1A1 in the preparation of a drug for relaxing airway smooth muscle.

[0005] In order to achieve the above-mentioned invention object, the technical solution adopted by the present invention is:

[0006] In a first aspect, the present invention provides the use of secretoglobin 1A1 in the preparation of a drug for relaxing airway smooth muscle.

[0007] Preferably, the secretoglobin 1A1 inhibits the contraction degree of airway smooth muscle by inhibiting the calcium response in smooth muscle cells, thereby exerting the effect of relaxing airway smooth muscle.

[0008] The contraction and relaxation of airway smooth muscle are crucial to respiratory function, and the regulation of calcium ion concentration in smooth muscle cells is an important mechanism for controlling the contraction and relaxation of smooth muscle. The present invention explores the intracellular calcium ion concentration through experimental exploration and finds that secretoglobin 1A1 can effectively reduce the calcium response in airway smooth muscle cells, thereby significantly inhibiting the degree of contraction of airway smooth muscle and achieving a good therapeutic effect of relaxing airway smooth muscle. This opens up the application of secretoglobin 1A1 in the preparation of drugs for relaxing airway smooth muscle, which has important clinical significance.

[0009] Preferably, the secretoglobin 1A1 is used to relax the contraction response of airway smooth muscles induced by cholinergic substances.

[0010] Preferably, the choline substances include carbachol and methacholine.

[0011] Preferably, the effective dose of secretoglobin 1A1 is 1-1000 μg / ml.

[0012] Preferably, the drug can be prepared into a clinically acceptable dosage form, which is at least one of an aerosol, a spray, a capsule, a tablet, a pill, a granule, a suspension and an injection.

[0013] In a second aspect, the present invention provides the use of secretoglobin 1A1 in preparing a reagent for inhibiting calcium response in smooth muscle cells.

[0014] In a third aspect, the present invention provides the use of secretoglobin 1A1 in the preparation of an agent for inhibiting contraction and deformation of smooth muscle cells.

[0015] In a fourth aspect, the present invention provides the use of secretoglobin 1A1 as an airway smooth muscle relaxant in the preparation of a drug for treating respiratory diseases.

[0016] Preferably, the respiratory disease is a respiratory disease caused by airway smooth muscle contraction.

[0017] Preferably, the respiratory disease comprises chronic obstructive pulmonary disease or asthma.

[0018] The present invention measures the tension of mouse tracheal rings by means of muscle tension measurement technology, and finds that pretreatment with secretoglobin 1A1 can effectively reduce the response of tracheal rings to the contraction-promoting inducer carbachol; in addition, animal experimental results show that administration of secretoglobin 1A1 can significantly reduce the tension of airway smooth muscles in pathological model mice, and thus can be used to treat respiratory diseases such as COPD caused by airway smooth muscle contraction or bronchial spasm.

[0019] In a fifth aspect, the present invention provides a drug for relaxing airway smooth muscle, the drug comprising secretoglobin 1A1 and a pharmaceutically acceptable excipient.

[0020] Preferably, the secretoglobin 1A1 inhibits the contraction degree of airway smooth muscle by inhibiting the calcium response in smooth muscle cells, thereby exerting a therapeutic effect of relaxing airway smooth muscle.

[0021] Compared with the prior art, the present invention has the following beneficial effects:

[0022] The present invention has discovered for the first time through experimental research that secretoglobin 1A1 can effectively reduce the contractile response of tracheal rings to choline substances, and revealed that secretoglobin 1A1 mediates airway smooth muscle relaxation by inhibiting calcium response in smooth muscle cells. In addition, secretoglobin 1A1 treatment can effectively reduce airway smooth muscle tension in COPD model mice, and thus can be used to treat respiratory diseases such as COPD caused by airway smooth muscle contraction or bronchospasm, which has important clinical significance. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 This is a statistical result diagram showing that secretoglobin 1A1 reduces the muscle tension response of tracheal rings to CCh (n=5);

[0024] Figure 2 Figure 1 shows the decrease in intracellular calcium in smooth muscle cells after pretreatment with secretoglobin 1A1 (Figure A) and the statistical results (Figure B) (n=6);

[0025] Figure 3 This is the statistical result of the effect of secretoglobin 1A1 pretreatment on the deformation of smooth muscle cells (n=6);

[0026] Figure 4 The statistical results show that secretoglobin 1A1 treatment reduces the tracheal muscle tension response in COPD mice (n=4). DETAILED DESCRIPTION

[0027] In order to make the purpose, technical scheme and effect of the present invention clearer and more specific, the present invention is further described in detail with reference to the following embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0028] Unless otherwise specified, the reagents used in the examples are conventional reagents in the art and can be purchased through commercial channels. The experimental operations not specifically described in the examples are conventional operations in the art or can be understood or known by those skilled in the art based on the existing technology or common knowledge they master.

[0029] Example 1. Study on the effect of secretoglobin 1A1 on reducing the contractile response of mouse tracheal rings

[0030] 1. Experimental animals: ICR mice, male, 20-30 g, purchased from the Experimental Animal Center of Sun Yat-sen University.

[0031] 2. Muscle tension detection method:

[0032] Mice were killed using CO2, and the trachea was separated and placed in HBSS solution (purchased from Gibco). The blood vessels and connective tissue were stripped off, and the trachea was trimmed into 2-3 mm small segments. The tracheal rings were washed with DMEM (purchased from Gibco) containing 1% penicillin-streptomycin (purchased from Gibco), and the trachea was pretreated with DMEM containing 10 μg / ml secretoglobin 1A1 (purchased from Solebol) and incubated at 37°C and 5% CO2. After 24 h, Krebs-Henseleit solution (containing 117 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 24.8 mM NaHCO3, 1.2 mM MgSO4, 1.2 mM KH2PO4, 11.1 mM D-glucose, pH = 7.4) was used to test the muscle tension of the tracheal rings; the tracheal rings were fixed in the HV-4 isolated tissue and organ constant temperature perfusion system through the vascular ring hook, and the tracheal rings were immersed in the solution at a temperature of 37°C and ventilated with 95% O2 and 5% CO2; the contraction tension was recorded using a tension transducer connected to a biological signal acquisition system. At the beginning of the experiment, 5mN pretension was first applied to the mouse tracheal rings, and the balance was performed for 20 minutes. The mouse tracheal rings were stimulated with different concentrations of 0.01μM, 0.1μM, 1μM, and 10μM carbachol (CCh, purchased from Sigma) to observe its effect on contraction tension.

[0033] 3. Data processing: The experimental data were presented as mean ± standard error (mean ± SEM). The data were tested using two-way ANOVA multiple comparisons. P < 0.05 was considered significant.

[0034] The results are as follows Figure 1 As shown, isolated mouse tracheal rings underwent stable and sustained pre-contraction under stimulation of different concentrations of CCh (0.1-10 μM), while the response of the tracheal rings to CCh was weakened after pretreatment of the mouse tracheal rings with secretoglobin 1A1, indicating that secretoglobin 1A1 can effectively reduce the contractile response of mouse tracheal rings.

[0035] Example 2. Study on the inhibition of calcium response of mouse airway smooth muscle cells by secretoglobin 1A1

[0036] 1. Experimental animals: ICR mice, male, 20-30 g, purchased from the Experimental Animal Center of Sun Yat-sen University.

[0037] 2. Research methods:

[0038] (1) Preparation of primary mouse airway smooth muscle cells

[0039] Mice were killed using CO2, the mouse trachea was isolated and the connective tissue around the trachea was peeled off under a stereoscope; the tracheal rings were cleaned using DMEM (purchased from Gibco) containing 1% penicillin-streptomycin (purchased from Gibco), the tracheal epithelium was gently scraped off using ophthalmic forceps, and the tracheal tissue was minced into a paste using ophthalmic scissors and spread on the bottom of the cell culture bottle, and cultured at 37°C, 5% CO2 for 4-5 hours. After that, 4 ml of DMEM-F12 medium (purchased from Gibco) containing 10% fetal bovine serum (FBS) was added to the culture bottle and cultured for another 4-5 days; thereafter, the medium was changed every 2 days until the cell density reached 80%.

[0040] (2) Determination of calcium ion concentration in primary mouse airway smooth muscle cells

[0041] Primary mouse airway smooth muscle cells were seeded in a 35 mm confocal dish (purchased from NEST) and cultured for 24 h; after 24 h, the medium was replaced with DMEM-F12 containing 1 μg / ml secretory globin 1A1 (purchased from Solebol) and cultured for another 24 h; the dish was removed and washed with NPSS solution (containing 137 mM NaCl, 5 mM KCl, 2.5 mM CaCl2, 10 mM HBSS, 1 mM MgCl2, 10 mM D-glucose, pH = 7.4) for 3 times, 5 min each time, and then incubated with flou-3AM for 1 h, and the intracellular calcium ion concentration was measured under a fluorescence microscope. The total measurement time was 6 min, and the images were taken every 15 sec. When measuring for 1 min, methacholine (MCh, purchased from Sigma) was added to the dish at a final concentration of 20 μM.

[0042] 3. Data processing: The experimental data were presented as mean ± standard error (mean ± SEM). For two groups of data, unpaired t test was used. P < 0.05 was set as a significant difference.

[0043] The results are as follows Figure 2 As shown, after pretreatment of primary cultured mouse airway smooth muscle cells with secretoglobin 1A1, the intracellular calcium response caused by MCh was significantly inhibited, and the intracellular calcium of smooth muscle cells was significantly reduced, indicating that secretoglobin 1A1 can mediate airway smooth muscle relaxation by inhibiting the intracellular calcium response of smooth muscle cells. Example 3. Study on the inhibition of contraction and deformation of human airway smooth muscle cells by secretoglobin 1A1

[0044] 1. Experimental materials: Primary cultured human airway smooth muscle cells.

[0045] 2. Research methods:

[0046] Primary human airway smooth muscle cells were seeded in a 35mm confocal dish (purchased from NEST) and cultured for 24 hours; after 24 hours, the medium was replaced with DMEM-F12 containing 1μg / ml secretory globin 1A1 (purchased from Solebol) and cultured for another 24 hours; the dish was removed and washed with NPSS solution (containing 137mM NaCl, 5mM KCl, 2.5mM CaCl2, 10mM HBSS, 1mM MgCl2, 10mM D-glucose, pH=7.4) for 3 times, 5 minutes each time, and the cell contraction deformation was measured under an inverted microscope. The total measurement time was 6 minutes, and the picture was taken every 15 seconds. When measuring for 1 minute, MCh (purchased from Sigma) was added to the dish, with a final concentration of 20μM.

[0047] 3. Data processing: The experimental data were presented as mean ± standard error (mean ± SEM). For two groups of data, unpaired t test was used. P < 0.05 was set as a significant difference.

[0048] The results are as follows Figure 3 As shown, after pretreatment of primary cultured human airway smooth muscle cells with secretoglobin 1A1, the cell contraction deformation caused by MCh was significantly inhibited, indicating that secretoglobin 1A1 can effectively inhibit the contractile response of smooth muscle cells.

[0049] Example 4. Study on the effect of aerosol inhalation of secretoglobin 1A1 on inhibiting the increase of airway smooth muscle tension in pathological model mice

[0050] 1. Experimental animals: C57BL / 6 mice, male, 20-30 g, purchased from the Experimental Animal Center of Sun Yat-sen University.

[0051] 2. Research methods:

[0052] (1) Construction of COPD mouse model

[0053] The mice were instilled with bacterial lipopolysaccharide (LPS, purchased from Sigma) at 1 mg / kg, 30 μl / mouse on day 0 and day 14. The mice were also continuously exposed to smoke for 16 weeks, with 12 cigarettes / hour for 4 hours a day, to establish a COPD mouse model.

[0054] (2) Secretoglobin 1A1 administration therapy

[0055] At the 12th to 16th week of smoke exposure, the model mice were treated with 1 mg / ml secretoglobin 1A1 (purchased from Solebol) by aerosolization. The aerosolization procedure was 7 ml / time, 30 min / time, 2 times / day. The control group was treated with the same amount of PBS by aerosolization.

[0056] 3. Data processing: The experimental data were presented as mean ± standard error (mean ± SEM). The data were tested using two-way ANOVA multiple comparisons. P < 0.05 was considered significant.

[0057] Airway hyperresponsiveness is an important feature of COPD. Therefore, this example uses COPD model mice as an example to investigate the effect of secretory globin 1A1 on airway smooth muscle tension under pathological model conditions. Figure 4 As shown, after nebulization treatment with secretory globin 1A1, the airway smooth muscle tension of model mice was significantly reduced, indicating that secretory globin 1A1 treatment can effectively reduce the airway smooth muscle tension of COPD model mice, and thus can be used to treat respiratory diseases such as COPD caused by airway smooth muscle contraction or bronchial spasm.

[0058] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.

Claims

1. Use of secretoglobin 1A1 in the preparation of a drug for relaxing airway smooth muscle.

2. Use of secretoglobin 1A1 in the preparation of reagents for inhibiting calcium response in smooth muscle cells.

3. Application of secretoglobin 1A1 in the preparation of reagents for inhibiting contraction and deformation of smooth muscle cells.

4. The use according to claim 1, characterized in that: The secretoglobin 1A1 is used to relax the airway smooth muscle contraction response induced by choline substances.

5. The use according to claim 1, characterized in that: The effective dosage of the secretoglobin 1A1 is 1-1000 μg / ml.

6. The use according to claim 4, characterized in that: The choline substances include carbachol and methacholine.

7. The use according to claim 1, characterized in that: The drug can be prepared into a clinically acceptable dosage form, which is at least one of an aerosol, a spray, a capsule, a tablet, a pill, a granule, a suspension and an injection.

8. Use of secretoglobin 1A1 as an airway smooth muscle relaxant in the preparation of drugs for the treatment of respiratory diseases.

9. The use according to claim 7, characterized in that: The respiratory system disease is a respiratory system disease caused by airway smooth muscle contraction, and the respiratory system disease includes chronic obstructive pulmonary disease or asthma.

10. A drug for relaxing airway smooth muscle, characterized in that: The drug comprises secretoglobin 1A1 and a pharmaceutically acceptable excipient.

Citation Information

Patent Citations

  • Application of dictamnine in preparation of medicine for relaxing precontracted tracheal smooth muscles

    CN110882248A

  • Methods and compositions for the treatment of fibrotic conditions and impaired lung function and to enhance lymphocyte production

    WO2001079285A1